UICC World Cancer Congress 2006

Objective: Non-invasive dual-modality imaging is a technique where anatomical imaging (Micro-CT or Micro-MRI data) is co-registered with physiological images (Micro-SPECT or Micro-PET) to provide an exact anatomical map of the in-vivo internal distribution of a radiopharmaceutical of interest. We have established an integrated molecular imaging laboratory where Micro-SPECT, Micro-CT, Micro-PET, and Micro-MRI data is fused allowing multi-modality anatomical-functional imaging of pre-clinical tumor models. Our goal is to demonstrate the utility of molecular imaging in evaluating the tumor targeting potential of new radiopharmaceuticals.

Methods: Using pre-clinical models of breast and prostate cancer we are evaluating In-111-DOTA-8-AOC-BBN(7-14)NH2, which has emerged as a potential diagnostic/therapeutic peptide analog that targets the BB2 receptor expressed in high concentrations in prostate and breast cancers. Micro-SPECT and Micro-PET technologies have been employed to generate three dimensional maps of radiopharmaceutical localization coupled with Micro-MRI and Micro-CT anatomical data. Longitudinal imaging studies are conducted as a rapid non-invasive means to determine in vivo drug pharmacokinetics.

Results: Using appropriate pre-clinical models, Micro-SPECT and Micro-PET can longitudinally assess in vivo drug pharmacokinetics. Micro-SPECT and Micro-PET data can be co-registered with anatomic images obtained from Micro-MRI and Micro-CT to generate a complete three dimensional functional drug uptake map coupled with exact anatomic location. These techniques permit the evaluation of new tumor targeted radiopharmaceuticals drugs in small animal models of disease which accurately replicate the behavior of human clinical disease. Biokinetic data from these studies can provide a better understanding of new pharmaceuticals for potential human use.